Find Novel Oncology Drugs in Discovery in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-AML specific antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kite Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 03, 2020

            Details:

            Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vir Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 24, 2020

            Details:

            HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $6,295.0 million Upfront Cash: $125.0 million

            Deal Type: Collaboration August 17, 2020

            Details:

            Under the expanded multi-year collaboration, Tango will continue to leverage its proprietary, CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets. The number of targets covered will expand from five to 15.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bispecific antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Seismic Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 04, 2020

            Details:

            Twist Biopharma will use Hyperimmune Libraries, two fully human antibody libraries focused on the heavy chain complementary determining region 3 (CDR3) loop diversity involved in antigen recognition, to identify antibodies that bind to the specified immuno-oncology targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Avoro Capital

            Deal Size: $70.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing August 03, 2020

            Details:

            The proceeds from the financing provides PMV Pharma with the resources to expand its pipeline and to potentially advance multiple p53 therapies into the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Viva Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 28, 2020

            Details:

            Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Immunotherapy compound

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 14, 2020

            Details:

            Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop dual-antigen targeting cancer therapies. Revitope is granting Junshi an exclusive license on products arising from the research collaboration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: $425.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 08, 2020

            Details:

            Under the collaboration agreement, Foghorn will grant Merck exclusive global rights to develop and commercialize drugs that target dysregulation of a single transcription factor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T Cell Engaging Bispecific Antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Xencor

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 08, 2020

            Details:

            Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 08, 2020

            Details:

            Under the pact Takeda will tap the Twist Bioscience's phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics across its four core areas: oncology, rare diseases, neuroscience and gastroenterology.

            PharmaCompass